Education
About Us
Working with TipRanks
Follow Us
Scandion Oncology A/S (DE:8VY)
:8VY
8VY Stock Chart & Stats
Day’s Range― - ―
52-Week Range<€0.01 - €0.01
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€85.59K
Enterprise Value-€11.98M
Total Cash (Recent Filing)€12.69M
Total Debt (Recent Filing)kr66.00K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
May 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding234,762,070
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.08
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
8VY FAQ
What was Scandion Oncology A/S’s price range in the past 12 months?
Scandion Oncology A/S lowest stock price was <€0.01 and its highest was €0.01 in the past 12 months.
What is Scandion Oncology A/S’s market cap?
Scandion Oncology A/S’s market cap is €85.59K.
When is Scandion Oncology A/S’s upcoming earnings report date?
Scandion Oncology A/S’s upcoming earnings report date is May 22, 2025 which is 60 days ago.
How were Scandion Oncology A/S’s earnings last quarter?
Currently, no data Available
Is Scandion Oncology A/S overvalued?
According to Wall Street analysts Scandion Oncology A/S’s price is currently Overvalued.
Does Scandion Oncology A/S pay dividends?
Scandion Oncology A/S does not currently pay dividends.
What is Scandion Oncology A/S’s EPS estimate?
Scandion Oncology A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandion Oncology A/S have?
Scandion Oncology A/S has 234,762,070 shares outstanding.
What happened to Scandion Oncology A/S’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scandion Oncology A/S?
Currently, no hedge funds are holding shares in DE:8VY
Company Description
Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of chemotherapy resistance. Its lead product candidate includes the SCO-101, an oral compound that is in clinical Phase Ib and Phase II studies in cancer patients. The company's other product candidate is SCO-201, which is in preclinical trial for the treatment of solid tumors. Scandion Oncology A/S was founded in 2017 and is headquartered in Copenhagen, Denmark.
LIDDS AB
―
Xintela AB
―
Lipigon Pharmaceuticals AB
―
CombiGene AB
―
Sprint Bioscience AB
―